dds c ,bc ]^ · 17 % cell growth dmbl 100.00 ppm dmbl 33.33 ppm dmbl 11.11 ppm control dmbl 3.70...

Post on 17-Mar-2020

38 Views

Category:

Documents

0 Downloads

Preview:

Click to see full reader

TRANSCRIPT

����DDS����� �������������������BNCT�

��!"#�$%&

'()*+*+

2

,-.$��/0

12DDS���3��45

,678

���

9:;<=>�?@AB

�������C-,DE5

FGHIJKLM=

FGHNOPQRSTO?@AB

FGHMIUB�

�V

-,DQRFGHWXMIUB�

T 67YZ67YZ67

FGHNOP�[\��]^

-,D�_`a/03,bc�]^C

deafgRhSTOijkgR

ilmknobc�]^50%pq�

-rsD/0tu4

vwFGHxy40 ppmpqvT/B>10tu4

vz��{|tXmk}~rs����i4�

v��w������S������i4�

v-rsD3����������_�100%

3

���������������

��FGHNOP���w�����FGHxyr��$�������� �����_h¡¢£¤¥�_`r¦§

¨©�ª«:¬@>���­®¯K°h.�h±²±h³´±hµ¶·±�

1� �����¸¹�º»t¼½¾¿FGHNOP�¿¼�DDStÀ�¾¿

��FGH[\��]^

wFGHxy>40 ppm �ÁÂ����ÃÄÅ�T/B>10 �BSH��1-1.5hBPA��3-4�

2��ÆÇ�ÈÉ3¾Ê�ËÌÍNDDS �-,D�_`a/0ÍtXmk?@ABh

9:;<=>�tXmk?@AB����

B-1: FGHIJKLM=B-2:FGHWX�DDSÏD

�����ijÐQR-,D�50Ñpqr/0ÒÓk

9:;<=>Î��Ôk67TOÕÖ×�t��¾h�������!h��Ø�ijÐ50%pq�ÙG�rÚÛ

C-1:-,D�MMB�Ü=>«BJC-2:9:;<=>�67TOÕÖ×�

4

vvw�FGHxy40 ppmpq�ÁÂ���¸¹�ÃÄÅ�vw3ÝÞ��FGHxy�ß T/B>10�àá��âÄ�

ÃÄÅ

u4wã

B-1:FGHIJKLM= B-2:FGHWX�DDSÏD���äå

��¾¿DDSt�æ¿,¤çÙG����

èé,67êFGHIJKLM=hHVJ-E, HVJ-MIUB�hFGHMIUB�rèé,67i

ëæÊ67wFGHxy40 ppmpqtu4

ÙG�ìêHVJ-E(BSH)�íØ����FGHxy40 ppmpq, T/B>10tu4FGHMIUB��áî���T/B>10tu4 (FGHxy�13.4 ppm �

vïðñWXñòó*ô���w��!�������������_tu4vFGHMIUB��áî��!������ijÐ{õ,�ö÷høùÙG��úû�Xüfýþtu4

5

FFGH�iFG�t��¾¿IJKLM=�FGHNOP

ï��*�ô�ïï*�ô�tFGHgRD3¾¿IJKLM=�FGHNOP

4-Boronophenylalanine Ethylester(BPA-OEt)

4-Boronobenzylcysteine Ethylester(BBC-OEt)

NH N

HNN

NHHN O O

HO NO

O

NaOONa

O

10BHO OH

10BHOOH

NH N

HNN

NHHN O O

HO NO

O

NaOONa

O S

10BHO OH

S

10BHOOHEC-028 EC-031

10B

COOEt

HO

OH

NH2 10B

SHO

OH

COOEt

NH2

��.� P. 98B-1:FGHIJKLM=���

6

FFGH.�� Jß�]±FGH�i�*�J�­=t��¾¿IJKLM=�FGHNOP

IJKLM={O��i�J�� J�tgR¾¿FGHNOP

4-Carboran-1-ylmethoxybenzoic acid (CMBA)

OC

HC

OH

O

: nBH

NH N

HNN

NN O O

HO NOHN

O

ONa

O

ONaOONa

O

O

NaO

O C

HC

: nBH

EC-032

��.� P. 100

7

��67ië�kFGHIJKLM=EC031, EC032���È�

��.� P. 103

8������������ ���

���� ��������������

� � ����������������

�����

FGHIJKLM=EC031(b�ue), EC032(red) �67wxy����N

67wFGHWX���g/108 cell)�

�>�67�U251:73.8 ppm

��.� P. 104

��.� P. 105

9

FFGHNOPQRHVJ-Envelope (HVJ-E) Vector���

���?@ABr� !Í

B-2:FGHWX�DDSÏD���

ñ#$%&'()**

����Pilot plant����

���� !

�+ �,+STOijk-.gR

T 67YZ67YZ67

-bc�/�N�

04211i,���¿¼�����i¤Â23

-Nucleocapsid, -Polymerase

HVJ-E (Empty vector)Wild type HVJ HVJ-E (+BSH)HN

F

Nucleocapsid(RNA, NP)

M

HVJPolymerase

(P, L)

45V

CÆ6/�DC¡7

SH

BSHSH

BSH

��.� P.127

HVJ-E��89:ê;<=>?@A�4BCÉ(�DEêFGàH�

10

Inactivation BSHLipid mixture

HVJ-liposome

Liposome with boronated compound

HVJ

SH

BSH

HVJ-liposome�I��89:ê9JM��4BCÉ(�DEêKaneda, Y., Dzau, VJ�

11

0

20

40

60

10 12 14 16

Added B (ug)Cel

l B c

once

ntra

tion

(ug

/g)

CT26 LM8

BSH delivery to cancer cells by HVJ-liposome

KL�rs67i40 ppmtMNkFGHxy�[\r!Í(HVJ-E�OPQ�

BSH�RS���TOU 0.12 – 0.18 Vg/107cells (4.8-7.2ppm)

��.� P. 131

12

W#$�X'ï'(�&()&YX%YZ�&

,

+,

[,

),

\,

],,

]+,

][,

]),

, ^ ], ]^ +, +^ _,

`Xa'%bY)X'ï'%c$Z&

ï'#ded'Y#$�X

Zfgf

Zfhf

ñòó'ZfYf

BSHQRHVJ-E�íØ���80 �g 10B/HVJ-E/tumor �

CT26��FGHxy

BSH �80 �g 10B��ìi�íØ��wxy:12-27 ppm

�xyê86.4 ppm(75.8 ppm at 1hr, 93.5 ppm at 1.5 hr)

��.� P. 133

13

ï*��c'j�X�&'(�&()&YX%YZ�&

,f,

+f,

[f,

)f,

\f,

],f,

]+f,

, ^ ], ]^ +, +^ _,

`Xa'%bY)X'ï'%c$Z&f

ï'#ded'k`�*)'j*��c

Zfgf

Zh

ñòó'ZfYf

CT26ìi�BSHQRHVJ-E�íØ��!�Ý�FGHxy

� ÝÞ�xyê0.5 ppm�

HVJ-E�íØ��!�Ý�xyê0.5 ppm

BSH�íØ��!�Ý�xyê0.6 – 1.1 ppm2000 �g 10B/body �lmw��24�n!�Ý�xyê0.6 ppm

��.� P. 133

14

��>���S��t�Si��¾¿ÙG�iñòó*ôeïðñt��w��!h�����

ijÐoDf�_rpqk

PBSPBS BSHBSH HVJHVJ--EE

ì

{|

��.� P. 161

15

FFGHMIUB����

double tail

H. Nakamura, Y. Miyajima, T. Takei, S. Kasaoka, K. Maruyama, Chem. Commun. (Hot paper) 2004, 1910.

hydrophilic part

rs��J�­=tu�À��XÌO4qvæwm濼xyai�æ ÓÊz¿FGH@­�AB�

ý{E5�| Ó¿rh�ö÷�| Óf�}¿~ý{E5�| Ó¿rh�ö÷�| Óf�}¿~FGHxy�FGHxy�7.2 mg/kg7.2 mg/kgr�����Æhr�����Æh14.4mg/kg14.4mg/kg������r| Ó¿~������r| Ó¿~

NaH

O OOH

B-2:FGHWX�DDSÏD���

�1��FGHMIUB������

16

n = 16: Stearoyln = 14: Parmitoyln = 12: Myristoyl

O NH

O

OO

O

H3C(H2C)n

O

H3C(H2C)n

S

2-O

M=�B����R

DMCBL (n = 12)DPCBL (n = 14)DSCBL (n = 16)

OS

O

OO

O

H3C(H2C)n

O

H3C(H2C)n

2-

DMBL (n = 12)DPBL (n = 14)DSBL (n = 16)

O Y

OS

2-

BC (Y = CH2)BCC (Y = NHCOCH2)

����FGHMIUB��$���

jÐ���jÐ����FGH.��WX��±zæ�FGH.��WX��±zæBSHBSHFGH@­�AB�À�FGH@­�AB�À�

BB1212HH1212SH (BSH)SH (BSH)

SH

2

--

Liposomes consist of phospholipids and cholesterol

(9�ê2006-186907h2006-275367h2006-259290�

��.� P. 108

17

% c

ell g

rowt

h

DM

BL

100.

00 p

pmD

MB

L 33

.33

ppm

DM

BL

11.1

1 pp

mD

MB

L

3.70

ppm

DM

BL

1.23

ppm

cont

rol

DPB

L10

0.00

ppm

DPB

L 33

.33

ppm

DPB

L 11

.11

ppm

DPB

L 3.

70 p

pmD

PBL

1.23

ppm

DSB

L

100.

00 p

pmD

SBL

33

.33

ppm

DSB

L

11.1

1 pp

mD

SBL

3.

70 p

pmD

SBL

1.

23 p

pm

DM

CB

L 1

00.0

0 pp

mD

MC

BL

33

.33

ppm

DM

CB

L

11.1

1 pp

mD

MC

BL

3

.70

ppm

DM

CB

L

1.2

3 pp

m

DPC

BL

100

.00

ppm

DPC

BL

3

3.33

ppm

DPC

BL

1

1.11

ppm

DPC

BL

3.70

ppm

DPC

BL

1.23

ppm

DSC

BL

100

.00

ppm

DSC

BL

3

3.33

ppm

DSC

BL

1

1.11

ppm

DSC

BL

3.70

ppm

DSC

BL

1.23

ppm

BSH

100.

00 p

pmB

SH

33

.33

ppm

BSH

11.1

1 pp

mB

SH

3.70

ppm

BSH

1.

23 p

pm

B(O

H)3

100.

00 p

pmB

(OH

)333

.33

ppm

B(O

H)3

11.1

1 pp

mB

(OH

)33.

70 p

pmB

(OH

)31.

23 p

pm

BC

100.

00 p

pmB

C33

.33

ppm

BC

11.1

1 pp

mB

C3.

70 p

pmB

C1.

23 p

pm

667�?J��ï�WE5

��'"%a`

"%a`

��.� P.110

18

ï* *Zh�a�$)���ï�^,�

]f,

],f,

],,f,

],,,f,

, + [ ) \ ], ]+ ][ ]) ]\

c%�a'%bY)X'ZXX%cZ%YZ�&

Y#$�X'g�*#$)'�$$_�

50%DPBL (5 mg 10B/kg)MIUB�t�æ¿BNCT���E5

Mice died.

Tumor disappeared!

control

DPBL(50%) Liposomes(5 mg10B/kg)

BSH (57 mg10B/kg)

PEGPEG--DPBL(50%)DPBL(50%)FGHMIUB��FGHMIUB������jÐ�xy�������rö÷jÐ�xy�������rö÷

�������ý{r�Æ�}¿��������ý{r�Æ�}¿�

ÙG�{õ,CT2667tÙG�����i¤çFGHPEGMIUB��5 mg 10B/����lm��h24hr!������30$�

�����V� �1.0 x 1012 n/cm2

19

FGHMIUB��ÙG�ilmk��ëjù����n!���wFGH���úxy

������������������������

������������������ �������

������������������������

������ �������������������

������������������� ����������

����������� ������������

����

��

����� ��

��������

�������

�������

�������

������

�������

�� ������

���

���

����

���

����

���

��

���

�����

� !

��

��

��

��

��

��

"#$%&

'(��)��*)�

�������

� ������������

��������� ��

�������� �������

����������

����������������

������������

�������� ��

+,-,

���./01�

2� ������34!"#$��

��.� P. 111

20

0.600.44

8.817.60.69

24h!�FGH�\�

à3�È�hXE�È�hàá�È��{5h25% or 50% DSBL (10-20 mg B/kg)tin vivo� ¡mkq3i¢3

£MIUB��£~¤wFGH$¥

DSBLê 50% 25%wê13.4ppm 22.6ppmÝÞ�ê0.76ppm 37.6ppm

��.� P. 111

21

,f,

],,f,

+,,f,

_,,f,

[,,f,

^,,f,

),,f,

¦,,f,

\,,f,

§,,f,

, + [ ) \ ], ]+ ][

�ðï�'+[`'+,$dïe¨d

(�&YX�*'`�Y

ñòó*�ðï�'^$dïe¨d

W©'+[`'+,$dïe¨d

+^ª�ðï�MIUB�øùñòó*FGHMIUB�t�æ¿ï�Wijk-E5 ¡

Tumor shrinkage

PEG

��!�;L

�\

��.� P. 113

22

,

],

+,

_,

[,

^,

),

¦,

\,

§,

],,

, ^ ], ]^ +, +^ _, _^ [,

�ðï��+^ª�`�Y

(�&YX�**(�*c

�ðï��^,ª�`�Y

ñòóô*�ðï�'

«¬­®!�¯rsÙG���úû

�����V� ,f§*]f['°'],]+ &e($+ ±V� ]f¦*+f]'²�

10mg10B/kg >42 days

0³´{ 8 days

5mg10B/kg

DSBL-FGHMIUB��XE�hHVJ-FGHMIUB��]^E5�¡D

��11��FGHMIUB�����FGHMIUB���ý{E5ý{E5�É~�É~�ö÷�| Óf�}¿~�ö÷�| Óf�}¿~

FGHxy�FGHxy�7.2 mg/kg7.2 mg/kgr�����Æhr�����Æh14.4mg/kg14.4mg/kg������r| Ó¿~������r| Ó¿~

Bioconjugate Chem. 2006, 17, 1310.

��.� P. 114

23

FGHNOP�wxy3T/Bß

HVJ-E(BSH)��ìi�íØ��� 32mg 10B/kg �ÙG�{õ,ê�xyê86.4 ppm, ÝÞ�xyê0.5 ppmÙG�µ0q�,ê�xyê135 ppm, ÝÞ�xyê0.5 ppmwFGHxy40ppmpq, T/B>10tu4BSH�ÙG�{õ,ìi�íØ��wxy:12-27 ppmhÝÞ�xyê0.6-1.1 ppm

�2��FGHMIUB��ÙG�{õ, ¶Ji�áî��20mg 10B/kg ��24�n!�wxyê13.4 ppm, T/B=17.6T/B>10tu4

��?@AB�ÙG�{õ, ¶Ji���� >40ppm, T/B>10 �u4�!Í��1���FGHMIUB�(Bioconjugate Chem. 17, 1314-20, 2006)7.2mg 10B/kg ��24�n!�wxyê23.1 ppm, T/B=2.3BSHQRTf-PEG-liposome (J. Control. Release 98, 195-207, 2004)35 mg 10B/kg ��72�n!�wxyê33.1ppm, T/B=6.0BSHQRPEG-liposome (J. Control. Release 98, 197-205, 2004)35 mg 10B/kg ��72�n!�wxyê24.3ppm, T/B=2.5

24

vv�����ijÐQR-,Dr50%pq/0ÒÓkv�������!h��Ø�ijÐ50%pq�ÙG�rÚÛ

ÃÄ

u4wã

C-1:-,D�MMB�Ü=>«BJC-2:9:;<=>�67TOÕÖ×�

���äå

vïððïtQR¾Ê�����mk3QR-rsD�§,ªpq�MMB�i4�v9:;<=>Î��Ôk67TO?@AB���i4�¾¿rhq�?@ABt�æ¿ï�Wijk��!h����_i·æÊ�h23¾¿��r��¸¹�º»�¿¼¼Â�zf�}¿~

¨!�lIvó½½*[�.�¾r¿À��h��t�Á�zkZÂ�Ôk~ÃĶBA3¾Êh-rsD39:;<=>�67TO×��ÅÆ,w{õ,t��¾hÇÈÙG�i67t�Ø�mk3ÚÛ�],,ª�Ô}¿��h45rÉÊÒÓk~

��E5vFGHNOPWXPEG-CG-HVJ-E�áî��ijÐ}~iz��{|t

XmkÙG����i4�

25

�4$MIUB��Ë100 nm��XV$È�3��Ì4�ÍÎÏÐ/�VÑÒ�âÄ�IRSI� � kirrad / kcont �Ó�íÔ

q�Ô¿Ð�Ì4ßrÕO/�V�ÖÓwmæ~

XChol

X DLO

PC XDSPC

0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1

0

0.1

0.2

0.3

0.4

0.5

0.7

0.6

0.8

0.9

1

1

0.9

0.8

0.7

0.6

0.5

0.4

0.3

0.2

0.1

0

OO

OO O P O

O O-N+

H H

Dilinoleoyl phosphatidylcholine(DLOPC)

OO

OO O P O

O O-N+

Distearoyl phosphatidylcholine(DSPC)

HO

H

H

H

Cholesterol (Chol)

�æ¿��� ×Ô�à3

MIUB�×4�ÍØÙ

Akamatsu, K., Effect of ionizing radiation on membrane permeability of liposome: the dependency of lipid composition, concentration, and radiation dose/dose-rate, Chem. Phys. Lipids, to be published.

��.� P. 116

C-1: �����ÁÚtÀ�¾¿-,D�Ü=>«BJMMB����

26

0

20

40

60

80

100

0 5 10 15 20 25Time for incubation (h)

Effl

ux (%

)

Û�����ijkFGH��WMIUB� �DLOPC: DSPC: BC: Chol = 20: 20: 20: 40 �Ó�høùDLOPC: DSBL: Chol = 20: 20: 60 �Ü��/ M=�ÝÞßàÞ�pH 7.4�� �-

,D�J�ª­á=�/0����Ü=>«BJ�£âãhä�åæ�~MIUB�çèÞxyê),'$éh],ïxyê],,,'hh$~

DLOPCt@NÊOFGHMIUB��������êÖÒÓfæ

-,D

10BWX��10B 10B

10B

10B10B

10B10B

10B

SO

O

H

H

H

S

O

OOC17H35

O

C17H35

OBC DSBL

«­ê«ëì3Chol�{O�íë«+êíëî­Q�«ëìWXïð��

��.� P. 123

27

MIUB�w�iïðñ3(%Xj�h*%YZ&tQRmk

À�ê10BñÖ��ò¿4He, 7Li×��hóôMIUB�Stõö¾Êæ÷~

���êø carboplatin�BSH3ùI¾Êúâi�/�N�ûü�mk~ý BSHxyrËæ3MIUB��Î4r¦§

(%Xj�h*%YZ&3þú�zk�N�ïðñ�ïððï��O4

B SHH2O2

2 Na+

: BH

2 Na+

B S BS

2 Na+

~ pH 11

28

ïððïQRMIUB��Û���ÑÒ�tO·v Û���K­�@�ê 1.64 x 109 n/cm2/s

v ���nê 4�n

v ��É��xyê ~ 10 mM

v çèÞw0³10B: 226 ppm

v çèÞw0³Ptxyê 8 ppm

Pt

Pt

Pt

PtPt

Pt

vMIUB�Ì4êDLOPC: DSPC: Chol = 2: 2: 6

Carboplatin

BSSB�10BFGHNOP�

/0

û�Ñ

0.9 % NaCl

�� �h9�2008-041048�ÏÐ/�V$È�MIUB�h�Ót�æ¿MIUB�ÏDhùiMIUB����� Akamatsu, K., Development of thermal neutron- sensitive liposome for a novel drug delivery system aiming for radio-chemo- concurrent cancer therapy, Radiat. Phys. Chem., to be published.

,

+,

[,

),

\,

],,

ïððïQRf¾���

ïððïQRf¾��

ïððïQRÔÐ���

ïððïQRÔÐ��

=�;?B>�

_¦�h[�n

ÏÐ/�VhÛ���ÑÒ��MIUB����øù��ijk-rsD�Ü=>«BJMMB���ÆÇ

��.� P. 125

29

C-2��9:;<=>�67TOÕÖ×����

*

N.S.

0

100

200

300

400

500

600

700

800

900

1000

0 5 10 15 20 25

Days after tumor inoculation

HVJ-E

AdVSaline

Suppression of CT26 growth in vivo by HVJ-E�Kurooka, M, Kaneda, Y: Cancer Research, 2008.�

Tumor-free mice

0

10

20

30

40

50

60

70

80

90

100:1 50::1 25:1 12.5:1 6:1 3:1

ET ratio

67���T 67��g

HVJ-E

Control

��.� P. 162

�200711�3;��1���16����

300

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1

0 5 10 15 20

Days after inoculation

HVJ-Eijk.�¥��ijÐùl������r�_

*

HVJ-E or saline injection into the right flank tumor

CT26 inoculationin the right flank

Day -4 Day 0 Day 4 Day 8

CT26 inoculationin the left flank

HVJ-E or saline injection into the right flank tumor

HVJ-E or saline injection into the right flank tumor

Monitor tumor formationat the left side

Rat

io o

f tum

or-f

ree

mou

se ��Ñ�ÙG��ö÷

31

HVJ-E

YZ67

NK

T 67

IFN-�,-�

NFkB

IL-6IFN-�,-�

Reg. T

NK67�/�N _`�T 67��_

,678

YZ67�/�N

CTL��g

HVJ-Eijk-J�r��

IFN-�?

��.� P.164

32

(A) Rantes

(B) IFN-��

(C) IL-12

©�*%'�hde$*�

,+,

[,),

\,],,

]+,

�*� WXZY�&',f] Wk\,',f,] Wk\,',f,+ Wk\,',f,^ Wk\,',f]

ñòó*ô

©�*%'�hde$*�

�*]+

*],

,

],

+,

_,

[,

�*� WXZY�&',f] Wk\,',f,] Wk\,',f,+ Wk\,',f,^ Wk\,',f]

ñòó*ô

�*]+'�hde$*�

½%&Y)a

*],,

,

],,

+,,

_,,

[,,

^,,

�*� WXZY�&',f] Wk\,',f,^ Wk\,',f] Wk\,',f+ Wk\,',f[

ñòó*ô

½%&Y)a'�hde$*�

HVJ-Eijk! >� =h® � =�g�QRi�ækDetergent�¸¹ij}Ê_`!Í

33

siRNA

Tf-F

Wild HVJ

HN (-)/Tf-F (+)HVJ

HN mRNA

HN-mRNAdegradation

Äa$�tX¾HNt"#¾¿ÄagRHVJ-E���J. Biotechnology 2008, BBRC, 2007, Human Gene Ther. 2007

Tf-Fstable transformant,

,f+

,f[

,f)

,f\

]

]f+

]f[

]f)

&�X$%* a(X%$j*) ñ�*aZ½��

X)*%YZg)'X%YZ�

Hemagglutinating Activity Assay

HN

Cont. SiRNA

F

HN"#3�Ý$%[��_

��.� P.148

��.� P. 145

(200718�5;�;1�������

34

HEK293(Low TfR) HeLa (High TfR)

Tumor-specific infection of HN-depleted targeting HVJ

HN-depleted HVJ with Tf-F

HN-depleted HVJ

Wb*© (`Z$)X%

©

��.� P. 149

35

Tf-F HVJ-E chimera HVJ-E

,

],

+,

_,

[,

^,

),

¦,

\,

§,

kZ**c (`Z$)X%

Y�Y%*'

&c�Y

Q-dotQRTf-F�J­HVJ-E���ÄaÍ� '

�lmw��!48�n�

¨!�Tfi�(kÄa$�t�æk

Tf-F HVJ-EijkQ-dot���w$¥

��Ì)h}~iPÝi 0��*�oåÌ)i� 0ÒÓô

Wild HVJ-E��+�~¤iO 0ÒÓô

��.� P. 150

36

CC NNOO

NHNH22

NHNH22

Cationized Gelatin ( CG)HVJ-E

+

CG-HVJ-E

�á,=N-­á=./HVJ-Eijkw0P1u

,

],,,

+,,,

_,,,

[,,,

^,,,

),,,

¦,,,

\,,,

§,,,

ñòó*ô ñòó*ô2²

*�$h`f

*#&d

*Zg)X

ah*))&

Tumor nodule

Liver Spleen

HVJ-E CG-HVJ-E

3�i{|t4·ÙG�

Intraperitonealinjection

�J. Gene Medicine, 7, 888-897, 2005) ��.� P.152

37

,^,,,,],,,,,]^,,,,+,,,,,+^,,,,_,,,,,_^,,,,

²*ñ

òó*ô

�X)Z$

$#&)

�&YZ*©'�j'�°]�

�&YZ*©'�j'�°[�

"�XY$

%&&Z&'̂,

"�XY$

%&&Z&'+^

�#(Zb)X%a)'%(YZgZY�'�½�

5�

CG-HVJ-Eijk67��Á�

TO89ilmk-���:;tmk3�_ÒÓkrh<=s! >B �=�D��>3s+�_ÒÓfæ

38

56�7689:;<;=>?@AB

0102030405060708090

100

0 10 20 30 40 50 60 70 80 90 100

?@C/

?@D

EF GF HF EF GF HF GF HF

ÙG���úû

Day

Surv

ival

Rat

io (%

)

PBS BLM CG/BLMHVJ-E/BLM

CG-HVJ-ECG-HVJ-E/BLM

CG-HVJ-E/BLM

BleomycinQRHVJ-E�3�w��ijk3S��,�����

(Mima, H., et al. and Kaneda, Y.: Mol. Cancer Ther. 2006)

38

39

Control Mice Survived Mice�Mol. Cancer Therapy, 2006)

IJKCT26LMNOPQ

×4: 0/4×4: 3/3

39

40

DXR DXR/HVJ-E

2/6 (33%) 0/10 (0%)Tumor

��úÙG�ÅÆi��Ø�

-rsDCHVJ-EijÐ��!�ÙG�i��Ø�

�%�', �

ÅÆ,67�?«�@�¤ç

ñòó*ôCs�UJA =s�UJA =RD

(Cancer Chemother. Pharmacol., 2008)

BC�ÅÆ, ¶Jië�k��E5

2/2

0/2

Tumor

Naive

HVJ-E/BLMtreated

�%�',

{õ,67�W+)�¤ç

D E �� ��

ñòó*ôvï�é�w�����3�w�

{õ,�� ¶Jië�k��E5

�BMC Medicine., 2008)

��.� P. 165

41

PEG{{O�á,=N-­á=./HVJ-ECH2

NH

C

NH

(CH2)3

N:H+Cl-

CH3

H3C

O

CH3

++ ++ ++

gelatingelatin(IEP=9.0)(IEP=9.0)

EDCEDC(1(1--ethylethyl--33--(3(3--dimethylaminopropyl)dimethylaminopropyl)--

carbodiimidecarbodiimide,, hydrochroridehydrochroride))

EthylenediamineEthylenediamine cationizedcationized gelatingelatin

CH3

CH2

NH

CH

N

(CH2)3

N:H+Cl-

CH3

H3C

NH2

CH2

CH2

NH2

NH2

CO

OH

NH2

C

O

NH

CH2

CH2

NH2

37 O C

pH 5

HVJ-EPEG

PEG-CG-HVJ-E

9�2007-157701,���A�@Jøù��Ï���ùi�Ót�æ¿ÏD(�DEêFGàHhFGHhIJKL �<M9:0�NONo. 12/054,200

42

}}£¤ ¶Jilmk12DDSt�æ¿BNCT

LM8G5�ÙG�tP67�7�w��14;!

ÙG�}~��z��{|

FGHNOPQR?@AB�áî��

Neutron

Boron compound(BSH)

SH

BSH

HVJ-E

SH

BSH

PEG./

�á,=N-­á=

43

}}£¤ ¶Jië�kFGHQR?@ABáî��!hï�Wijk��E5

Liver Weight (g)

0 1 2 3 4

PEG-CGHVJ-E

CGHA-HVJ-E

CG-HVJ-E

HVJ-E

BSH

normal liver

BNCT(-)

Control Normal Liver BSH

HVJ-E CG-HVJ-E PEG-CG-HVJ-E

10B concentration:BSH; 1,000 �gB/ headHVJ-E BSH, Polymer HVJ-E BSH; 13.6 �gB, 1,500 HAU/head

(QRÎ4��

��.� P. 160

44

FFGHNOPgR!�}~Ì)t�����¾h9JK°BV�s�>t 0

Tumor

NormalLiver

BSH 750 �gB BSH 30 �g B PEG-CG-HVJ-E BSH 25 �gB

45

BSHQQRPEG-CG-HVJ-E t�æ¿BNCT��!�S,ÙG�}~Ì)

Normal Liver

Tumor

zL�M=T$�UV

4646

�����45i·æÊ

[\��ËæFGHDDSÏD���

-rsD�Ü=>«BJMMB����

ÃÄ�u4y

45�üW

XaYZ[�\]f+

45�^ø

vFGHNOPQRHVJ-E�Ì)i�

íØ��ijÐ�·�ÃÄÅt@M9vFGHMIUB��áî��ijÐT/B>10t@M9vFGHIJKLM=hBSHQRHVJ-liposome�èé,67iëæÊ67wFGHxy40 ppmpqt@M9~

v-rsD�MMB�Ü=>«BJ�ÃÄÅt@M9�zkMIUB�t��v9:;<=>�67TOÕÖ×�t��vBNCT!��Ø�����_Â

v.`�.�¾�º»�¿¼~¿ÀmÓa��t�Á�zkbc�de~v9:;<=>�67TO×�3-rsD���¾¿ÙG���Ø�!�ÚÛû�100%~

vBSH/HVJ-Et�æ¿BNCT����¦§f

���S���f1a��3fÐgk~vFGHMIUB��BNCTië�káî��

�?@ABifÐgk~vBSH/HVJ-E, FGHMIUB�th�mÓa

Ô ikj×rs���lÚ3fÐgk~v,a�Ð�f÷Ýk�lmwÍ|MGÙáf+���iOXE�rËæ3ÄN Ók~

v-rsD�Ü=>«BJMMB�MIUB���ÆÇ~qÓ�ÏÐ/�ViOÑÒ�rÔÐ/�V��áyin��rÔk~v9:;<=>�67TOÕÖ×���ÆÇ~*�?@AB��q�jgfÌÍ�X¾fæ~qÓijÐ,�¡¢£¤¥��_w������ ��rsO�_�zh�·,�2oO!ÍifÐhàáà7f�/��Ái�pq±~

Mw0�9:D¹�Mr0�1¹��FGHMIUB�3¹h���vÏÐ/�VÑÒ�MIUB�h,���A�@J�

vQR�å�h=Rs�QR44t�s�f¾16t�huv11tvµ&�å�Mw81¹hM523¹v1��å�5¹(FGHMIUB�3BNCTr3¹hÄaNHVJ-E, 9:;<=>E5)

47

DDSÏÏD���N�|õ¾

HVJ-E��BTB9w���� B�id0�;NO�D�

20091 20101 20151 20201

FGHMIUB�

IMÙBHVJ-E

RD������ RD���� �:¬Ö¯¶L9x�

GLP����

��������,��������S��hy�z{h

{õ,�}£¤f+

���ÏDÏ���|B

GLP�����������ijk,�������

FGHIJKLM=

BSH�� ���­K°BÙx�y�z{GLP���È�

top related